Summary
Blood of 16 patients with essential thrombocythemia (ET), 9 patients with reactive thrombocytosis (RT) and 13 healthy persons was used for platelet aggregation studies. When the aggregation was induced with adenosine diphosphate (0.01 µM), collagen (0.1 µg/ml) or platelet activating factor (PAF 0.5 µM) the plasma of the patients with ET showed significantly decreased aggregation (35%–44% of the value for the control groups). Independent of inhibitors of platelet aggregation, thrombin (0.05 U/ml) caused similar aggregation in healthy controls and patients with ET; patients with RT showed an increased aggregation. Adrenalin-induced aggregation discriminated best between patients with ET and controls. Adrenalin in concentrations ranging from 0.01 µg/ml to 100 µg/ml caused comparable dose-related amounts of aggregation in healthy controls and patients with RT. Over the whole concentration range, patients with ET showed significantly decreased aggregation (28%–34% of the value for the control groups). This difference proved to be independent of the influence of inhibitors of platelet aggregation. Though concentrations of alpha1-acid glycoprotein never reached inhibitory levels in the plasma of patients with ET (n=12) they were significantly higher compared with those in normal plasma (n=12). Fibrinogen concentrations in plasma of ET-patients (n=12) were in the normal range. Cellular adenosine 3′–5′-cyclic monophosphate concentrations in ET (n=10) are comparable with normal values (n=5). The significance of the results for diagnosis and better pathophysiological understanding of ET is discussed.
Similar content being viewed by others
Abbreviations
- ADP:
-
Adenosindiphosphat
- cAMP:
-
zyklisches Adenosin-3,5′-monophosphat
- ET:
-
essentielle Thrombozythämie
- IBMX:
-
Isobutyl-methyl-xanthin
- PAF:
-
Plättchen aktivierender Faktor
- PFP:
-
Plättchenfreies Plasma
- PRP:
-
Plättchenreiches Plasma
- RT:
-
Reaktive Thrombozytose
Literatur
Adam O, Dill-Wiesner M, Wolfram G, Zöllner N (1980) Plättchenaggregation und Prostaglandinumsatz beim Menschen unter definierter Linolsäurezufuhr mit Formeldiäten. Res Exp Med 177:227–235
Baumann B (1987) Untersuchungen zu Thrombozytenfunktion bei essentieller Thrombozythämie und reaktiver Thrombozytose. Dissertation zum Erwerb des Doktorgrades der Medizin an der Ludwig-Maximilians-Universität zu München
Berrettini M, Parise P, Constantini V, Grasselli S, Nenci G (1985) Platelet Activation in Psoriasis. Thromb Haemostas 53(2):195–197
Becker W, Rapp W, Schwick HG, Störiko K (1968) Methoden zur quantitativen Bestimmung von Plasmaproteinen durch Immunpräzipitation. Z Klin Chem Biochem 6:113–122
Born GVR, Cross MJ (1963) The Aggregation of Blood Platelets. J Physiol 168:178–195
Boughton BJ, Corbett WEN, Ginsburg AD (1977) Myeloproliferative Disorders: a paradox of in-vivo and in-vitro platelet function. J Clin Path 30:228–234
Chesney CM, Pifer CD, Much KM (1985) Desensitization of Human Platelets By Platelet Activating Factor. Biochem Biophys Res Comm 127(1):24–30
Cox CP, Linden J, Said SJ (1984) VIP elevates Platelet Cyclic AMP Levels and Inhibits In-Vitro Platelet Activation induced by Platelet-Activating Factor. Peptides 5:325–328
Di Minno G, Silver MJ, Carbone A, Riccardi G, Rivellese A, Mancini M, Thiagarajan P (1985) Increased Binding of Fibrinogen to Platelets in Diabetes: The Role of Prostaglandins and Thromboxane. Blood 65(1):156–162
Fabris F, Randi MC, Sbrojavacca R, Casonato A, Girolami A (1981) The Possible Value of Platelet Aggregation Studies in Patients with Increased Platelet Number. Blut 43:279–285
Ginsburg AD (1975) Platelet Function in Patients with High Platelet Counts. Ann Intern Med 82:506–511
Greco NJ, Arnold JH, O'Dorisio TM, Cataland S, Panganomala RV (1985) Action of Platelet Activating Factor on Type 1 Diabetes Human Platelets. J Lab Clin Med 105:410–416
Handin RJ, Cooper B, Young L, Alexander RW (1978) Regulation of the human platelet alpha-adrenergic receptor. Clin Res 26:348A
Hehlmann R, Jahn M, Baumann B, Hillmar I, Köpcke W (1987) Untersuchungen zur Diagnose und Differentialdiagnose der essentiellen Thrombozythämie. Klin Wochenschr 65 (Suppl IX):185–186
Hehlmann R, Jahn M, Baumann B, Hillmar I, Köpcke W (1988) Essential Thrombocythemia: Clinical Characteristics and Course of 61 Cases. Zur Veröffentlichung eingereicht
Hillmar I, Muramatsu T, Zöllner N (1984) Effects of a Thio Analog of Platelet-Activating Factor on Platelet Aggregation and Adenosine 3′,5′-Monophosphate Concentration in Hepatocyte Suspensions and in Platelets. Hoppe-Seyler's Z Physiol Chem 365:33–41
Holmsen H, Dangelmaier CA, Holmsen KH (1981) Thrombin-induced Platelet Responses Differ in Requirement for Receptor Occupancy. J Biol Chem 256:9393–9396
Hussain S, Schwartz JM, Friedman SA, Chua SN (1978) Arterial thrombosis in essential thrombocythemia. American Heart J 96(1):31–36
Jahn M (1987) Untersuchungen zur klinischen Charakterisierung und Abgrenzung der essentiellen Thrombozythämie. Thesis Universität München, 1987
Jahn M, Zönnchen B, Köpcke W, Hehlmann R (1988) Untersuchungen zur klinischen Charakterisierung und Abgrenzung der essentiellen Thrombozythämie. Klin Wochenschr 66:190–198
Kaywin P, McDonough M, Insel PA, Sanford JS (1978) Platelet Function in Essential Thrombocythemia. N Engl J Med 299:505–509
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein Measurement with the Folin Phenol Reagent. J Biol Chem 193:265–275
Marcus AJ (1969) Platelet function. Second of three parts. New Engl J Med 280:1278–1284
Marx R (1980) Beeinflussung der Thrombozytenfunktion. Therapiewoche 30:4666–4675
Murphy S, Iland H, Rosenthal D, Laszlo J (1986) Essential Thrombocythemia: An Interim Report from the Polycythemia Study Group. Seminars in Hematology 23(3):177–182
O'Brien JR, Oxon DM (1968) Effects of Salicylates on Human Platelets. Lancet (1):779–783
O'Regan S, Rivard GE, Mougean JG, Robitaille PD (1979) A circulating inhibitor of platelet aggregation in Bartter's Syndrome. Pediatrics 64(6):939–941
Pareti FJ, Gugliotta L, Mannucci L, Guarini A (1982) Biochemical and Metabolical Aspects of Platelet Dysfunction in Chronic Myeloproliferative Disorders. Thromb Haemostas 47(29):84–89
Preston FE (1982) Essential thrombocythaemia. Lancet 1:1021
Schafer AJ (1984) Bleeding and Thrombosis in the Myeloproliferative Disorders. Blood 64:1–12
Snyder ST, Coodley EL (1976) Inhibition of Platelet Aggregation by Alpha1-Acid Glycoprotein. Arch Intern Med 136:778–781
Tangen O, McKinnon EL, Berman HJ (1973) On the fine structure and aggregation requirements of gel filtered platelets. Scand J Haematol 10:96–102
Tovey KC, Oldham KG, Whelan IAM (1974) A simple direct assay for cyclic AMP in plasma and other biological samples using an improved competitive protein binding technique. Clinica Chimica Acta 56:221–234
Valle D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, Maillard JN, Pariente A, Leporrier M, Rueff B, Muller O, Benhamou JP (1985) Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 103:320–324
Vermylen J, Badenhorst PN, Deckmyn H, Arnout J (1983) Normal Mechanisms of Platelet Function. Clinics in Hematology 12:107–151
Wu KK (1978) Platelet Hyperaggregability and Thrombosis in Patients with Thrombocythemia. Ann Intern Med 88:7–11
Yamamoto K, Sekiguchi E, Takatani O (1984) Abnormalities of Epinephrine-Induced Platelet Aggregation and Adenine Nucleotides in Myeloproliferative Disorders. Thromb Haemostas 52(3):292–296
Author information
Authors and Affiliations
Additional information
Herrn Prof. Dr. N. Zöllner zum 65. Geburtstag gewidmet
Rights and permissions
About this article
Cite this article
Baumann, B., Hillmar, I. & Hehlmann, R. Untersuchungen zur Thrombozytenfunktion bei essentieller Thrombozythämie und reaktiver Thrombozytose. Klin Wochenschr 66, 199–207 (1988). https://doi.org/10.1007/BF01728197
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01728197